Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mixed amphetamine salts is a central nervous system (CNS) stimulant composed of four different amphetamine salts: dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate. It is primarily indicated for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. The drug works by increasing the synaptic concentrations of norepinephrine and dopamine through several mechanisms: it acts as a competitive inhibitor of the dopamine transporter (DAT) and norepinephrine transporter (NET), promotes the release of these neurotransmitters from presynaptic neurons, and inhibits their sequestration into vesicles via the vesicular monoamine transporter 2 (VMAT2). Additionally, it acts as an agonist at the trace amine-associated receptor 1 (TAAR1). The mixture typically contains a 3:1 ratio of dextroamphetamine to levoamphetamine isomers, which is intended to provide a balanced therapeutic effect on focus and alertness while managing peripheral side effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mixed amphetamine salts (Takeda, 0454e2).